Multidisciplinary Strategies in RCC Management: Future Directions in Care
Closing out their discussion on renal cell carcinoma, key opinion leaders highlight the value of multidisciplinary care and look toward future evolutions in the treatment paradigm.
Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence
Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.
Combination IO TKI Therapy in Patients With Metastatic Renal Cell Carcinoma
Focused discussion on combination IO-TKI therapy and its role as first-line therapy in patients diagnosed with metastatic renal cell carcinoma.
Scenario 2: A 59-Year-Old Man With Favorable Risk Metastatic RCC
Moving on to the second patient scenario of renal cell carcinoma, panelists reflect on the treatment pathway for favorable risk metastatic disease.
Role of Combination Immunotherapy in Metastatic Renal Cell Carcinoma
Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.
Scenario 1: A 47-Year-Old Man With Intermediate Risk Metastatic RCC
Expert perspectives on a patient scenario of intermediate risk metastatic renal cell carcinoma and corresponding management with combination immunotherapy.
Dr. Hammers on Immunotherapy Combinations in Kidney Cancer
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses combinations with immunotherapy being investigated for patients with kidney cancer.
Dr. Hammers on Next Steps with Immunotherapy in RCC
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the next steps with immunotherapy for patients with renal cell carcinoma (RCC).
Dr. Hammers on the Future of Treatments for RCC
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of treatments for patients with renal cell carcinoma (RCC).
KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
2 Clarke Drive Cranbury, NJ 08512